>
>
Blood Screening Market - By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories) – Global Forecast, 2024-2032
Download Free PDF

Blood Screening Market
Get a free sample of this reportGet a free sample of this report Blood Screening Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 13
Tables & Figures: 522
Countries covered: 22
Pages: 280
Download Free PDF
Blood Screening Market Size
Blood Screening Market size was valued at around USD 3.2 billion in 2023 and is anticipated to register a CAGR of 7.3% between 2024 and 2032. This robust market growth can be attributed to various factors, including the continual technological advancements, rise in blood donation activities, increasing prevalence of infectious diseases, surging demand for blood transfusion diagnostics procedures, and growing healthcare infrastructure.
Moreover, the continuous incidences of infectious diseases such as HIV, hepatitis, and syphilis needs strict blood screening methodology. As these diseases can spread through blood transfusions, proper screening is critical in preventing their propagation. For instance, according to World Health Organization (WHO), by the end of 2022, around 39.0 million individuals were infected with HIV. Out of which 1.5 million are HIV-positive children (0-14 years old).
Furthermore, an increase in medical operations, surgeries, and treatments, such as organ transplants and cancer therapies, contributes to a greater need for safe and appropriate blood-related products. Thus, there is a greater demand for complete blood testing at regular intervals for patients undergoing different treatments.
Blood screening refers to the process of testing a blood sample to assess various parameters and detect the presence of specific substances or conditions within the blood. The main objectives of blood screening is to ensure the safety of blood transfusions, identify potential health issues, and monitor specific markers that may indicate diseases or infections.
COVID-19 Impact
The COVID-19 pandemic had a slightly positive impact on the blood screening market. Owing to the growing awareness towards infectious disease diagnostics has underscored the critical importance of rigorous blood screening protocols, contributing to increased demand for screening services to ensure the safety of blood transfusions. Additionally, the pandemic has prompted innovations in point-of-care testing and accelerated the adoption of automation in different screening processes. Overall, the market has experienced shifts in demand, technological emphasis, and operational strategies as it continues to adapt to the evolving healthcare landscape shaped by the global health crisis.
Blood Screening Market Trends
The continuous technological advancements, such as the integration of nucleic acid testing (NAT) and other molecular diagnostic techniques, growing demand for point-of-care testing, rising need for infectious disease screening, and surging demand for integrated artificial intelligence (AI) in healthcare and machine learning applications. These factors collectively contribute to the evolving landscape of the market.
Blood Screening Market Analysis
The market by product is segmented into reagents & kits, and instruments. The reagents & kits segment is further divided into NAT reagents & kits, ELISA, and other reagents & kits. The reagents & kits segment accounted for majority revenue share and was valued at around USD 2.4 billion revenue in 2023.
Based on technology, the blood screening market is categorized into nucleic acid test, serology/immunoassays, rapid test, western blot assays, and next generation sequencing. The nucleic acid test segment is further bifurcated into transcription-mediated amplification and real-time PCR. The serology/immunoassays segment in further divided into chemiluminescence immunoassay, fluorescent immunoassays, and colorimeter immunoassays/ELISA. The nucleic acid test segment dominated the market and accounted for over 43% business share in 2023 and is anticipated to witness significant growth during the forecast period.
The blood screening market by end-use is categorized into hospitals, blood banks, and pathology laboratories. The blood banks segment accounted for over USD 1.7 billion revenue size in 2023.
North America blood screening market accounted for USD 1.3 billion revenue in 2023 and is predicted to witness substantial market progression.
Blood Screening Market Share
The blood screening industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, F. Hoffmann-La Roche Ltd., Grifols, S.A., Hologic, Inc., QIAGEN N.V., among others have a notable presence in the market.
Blood Screening Market Companies
Some of the eminent market participants operating in the blood screening industry include:
Blood Screening Industry News:
Blood screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Product, 2018-2032 (USD Million)
By Technology, 2018-2032 (USD Million)
By End-use, 2018-2032 (USD Million)
The above information is provided for the following regions and countries: